24 June 2021
2021 Webinar | Why you should consider controlling your potentially mutagenic impurities outside the lab
We are delighted to have Andrew Teasdale PhD presenting within this webinar; Why you should consider controlling your potentially mutagenic impurities outside the lab.
Andrew is currently the chair of AstraZeneca’s Impurity Advisory Board and has a wealth of knowledge developed over the last 20 years of working within the pharmaceutical industry. He is a leading AZ expert for a number of key impurity areas, including mutagenic impurities (MIs).
Andrew’s presentation will cover the following topics:
- The challenges of controlling potentially mutagenic impurities
- How using the paper-based approach can reduce the time and effort associated with these challenges
- AstraZeneca’s experience of how Mirabilis can help further
- Top tips for applying control option 4.
This presentation will be followed by a short Mirabilis software demonstration from Raeesah Saddiq, Lhasa Business Development Executive.
After the presentations we will hold a live Q&A session.
This virtual event will begin at 16:00 (UK time) and will last approximately 90 minutes.
Headline Event (shown first above featured)